Tokyo Tape
Sign in
← AuBEX

Half-year report · Q2

3583.TEDINET S100UOJ8
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥3.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥5.4bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥2.6bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥489m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥270m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥454m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥601m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥294m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥452m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥294m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥302m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥436m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥218m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥302m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥218m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥9.6bnat 2024-09-30Cons.Assets
Total assets¥9.7bnat 2024-03-31Cons.Assets
Total assets¥9.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥3.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥3.5bnat 2024-03-31Cons.Liabilities
Net assets / equity¥6.5bnat 2024-09-30Cons.Net assets
Net assets / equity¥6.3bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥3.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥2.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.4bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥313m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥601m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥202m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥165m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥99m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥391m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥451m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥139m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥108.12024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥156.82023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥78.212023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio67.6%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio64.4%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥817m
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥817m
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥513,000
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30¥65m
jpcrp040300-q2r_E00584-000Technological Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E00584-000Technological Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E00584-000Technological Productsreportable segmentsegment profit2024-04-01 → 2024-09-30¥598m
—segment totalrevenue2024-04-01 → 2024-09-30¥3.0bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥3.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥513,000
—segment totalsegment profit2024-04-01 → 2024-09-30¥663m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥3.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥3.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥513,000
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥663m
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥721m
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥720m
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥645,000
jpcrp040300-q2r_E00584-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30¥48m
jpcrp040300-q2r_E00584-000Technological Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00584-000Technological Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00584-000Technological Productsreportable segmentsegment profit2023-04-01 → 2023-09-30¥382m
—segment totalrevenue2023-04-01 → 2023-09-30¥2.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥2.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥645,000
—segment totalsegment profit2023-04-01 → 2023-09-30¥430m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥2.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥2.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥645,000
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥430m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 518
ItemContextValueUnit
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所スタンダード市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数は100株であります。
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)昭和化学工業㈱
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)東京都港区赤坂２－14－32
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)㈱麻生
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)福岡県飯塚市芳雄町７－18
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)若築建設㈱
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)東京都目黒区下目黒２－23－18
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)㈱日本カストディ銀行（信託Ｅ口）
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)東京都中央区晴海１－８－12
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)オーベクス取引先持株会
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)東京都墨田区両国４－31－11
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)㈱みずほ銀行(常任代理人 ㈱日本カストディ銀行)
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)東京都千代田区大手町１－５－５(東京都中央区晴海１－８－12)
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)大塩 学而
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)長野県松本市
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)栗原 則義
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)千葉県八千代市
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)三井住友信託銀行㈱(常任代理人 ㈱日本カストディ銀行)
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)東京都千代田区丸の内１－４－１(東京都中央区晴海１－８－12)
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)オーベクス従業員持株会
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)東京都墨田区両国４－31－11
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)オーベクス株式会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)東京都墨田区両国４－31－11
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Type1 semi annual consolidated financial statements financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus
Quarterly consolidated statement of cash flows (text)CurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass